2020 Journal Citation Report Released

Posted on by

The new 2020 Journal Citation Report (JCR) was released on June 29 by Clarivate Analytics, providing the 2019 Impact Factor for journals.  The Impact Factor is based on the ratio of a journal’s citations in a given year to the journal’s total number of citable items from the previous two years. 

The JCR also ranks journals by subjects, enabling us to view journal impact within a specific subject category, such as Oncology.  Shown here are the top 10 journals in Oncology out of the 244 listed in this category, along with the number of MSK-affiliated publications for each journal in 2019. 

  1. CA: A Cancer Journal for Clinicians (2)
  2. Nature Reviews Clinical Oncology (6)
  3. Nature Reviews Cancer (5)
  4. Lancet Oncology (25)
  5. Journal of Clinical Oncology (60)
  6. Cancer Discovery (20)
  7. Cancer Cell (18)
  8. JAMA Oncology (34)
  9. Annals of Oncology (38)
  10. Molecular Cancer (1)

Contact us to find out more about the JCR. 

New Journal – Health Environments Research & Design (HERD)

Posted on by

The Library has added a new journal title to the collection, Health Environments Research & Design (HERD). HERD features evidence-based, interdisciplinary research on “relationships among health and environmental design and organizational, provider, and patient outcomes.”

Major topics in this journal include healthcare innovations and design, industry challenges that affect patient outcomes, and enhancement of working conditions for healthcare professionals. 

Exercise for Reducing Cancer Death Risk, Vitamin D for Immunotherapy Enhancement and More

Posted on by
  • Researchers from several academic institutions in the U.S. conducted a prospective cohort study on the impact of physical activity on cancer. It demonstrated that physical inactivity, or a greater sedentary lifestyle, was associated with higher (up to 82%) cancer mortality. At the same time, a moderate intensity exercise reduced the risk of cancer death by 31%. The study was published in Lancet Oncology.
  • Colitis is a known digestive tract side effect of immunotherapy in cancer treatment. A new study by U.S. researchers established that vitamin D supplementation before starting cancer treatment reduced the risk of developing colitis in patients treated with immune checkpoint inhibitors by 65%. This study was published in Cancer. 
  • A novel formulation of an existing drug abiraterone acetate used for prostate cancer (currently available as a commercial product Zytiga) can make a significant impact on the quality of life of patients treated with it. Australian scientists enhanced the drug’s properties “by using oils to mimic pharmaceutical food effects,” leading to fewer side effects and smaller doses needed for treatment. This preclinical study was published in the International Journal of Pharmaceuticals.
  • Scientists from Europe established that “targeting cancer’s ability to process fat” by using a combination of a new class of drugs called cPLA2 inhibitors and a fat free diet makes cancers less reliant on fat for their growth and spread. This animal study was published in Cell.